Q2 STOCKS TO BUY

Analysts Chime In on Big Pharma Ahead of Earnings

PFE said it would delay raising drug prices after a Trump tweet

Jul 11, 2018 at 10:51 AM
facebook X logo linkedin


Analysts are weighing in on big pharma today, with AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) among the names in the spotlight. Attention for the former is more upbeat, while notes for the latter are tilted toward the skeptical side -- even after both stocks' recent run up the charts.

Diving deeper, J.P. Morgan Securities said strong quarterly earnings results for drug companies will likely be offset the recent strength in the U.S. dollar. The brokerage firm believes Pfizer will be among those most negatively impacted by forex issues, while Abbvie -- and Eli Lilly (LLY) -- will see a more modest headwinds.

Elsewhere, SunTrust Robinson expressed concern over Pfizer's announcement that it will delay hiking drug prices for up to six months, after its CEO talked to President Donald Trump following a scathing POTUS tweet. The brokerage firm maintained its "hold" rating on PFE stock, while saying to accumulate shares of ABBV -- which it rates a "buy" -- given the latter's volume-driven sales growth on new products.

At last check, PFE was trading down 0.5% at $37.23, with traders also reacting to news the big-cap pharma name plans to split into three companies in order to separate its consumer healthcare business, which it's been trying to sell since 2017. More broadly, the shares have been swinging higher since their early May lows, up 8.4%.

ABBV, meanwhile, has plunged 2.5% today to trade at $96.35. News the company's cancer drug, Imbruvica, failed in a late-stage study is offsetting the upbeat analyst attention, with the shares on track to snap their eight-day win streak -- their longest since March 2017. Nevertheless, the drug stock is still churning below its 200-day moving average, which has kept a tight lid on the equity since mid-June.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter